{"url_path":"/sec/fate/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-220691-index.html","accession_number":"0001193125-26-220691","cik":"0001434316","ticker":"FATE","issuer_name":"FATE THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-220691-index.html","primary_entity_key":"0001434316","primary_entity_name":"FATE THERAPEUTICS INC"},"word_count":81,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit No.\n\nDescription\n\n99.1\n\n[Press release dated May 13, 2026](fate-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nFATE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 13, 2026\n\nBy:\n\n/s/ Bahram Valamehr\n\n \n\n \n\n \n\nBahram Valamehr, Ph.D., MBA\nPresident and Chief Executive Officer"}